SCYX - SCYNEXIS INC
IEX Last Trade
1.01
0.009 0.881%
Share volume: 1,879
Last Updated: Fri 27 Dec 2024 08:01:38 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$1.00
0.01
0.89%
Fundamental analysis
34%
Profitability
43%
Dept financing
15%
Liquidity
75%
Performance
20%
Performance
5 Days
0 0%
1 Month
-25.55%
3 Months
-33.33%
6 Months
-49.75%
1 Year
-48.74%
2 Year
-32.89%
Key data
Stock price
$1.01
DAY RANGE
$1.00 - $1.02
52 WEEK RANGE
$1.02 - $3.07
52 WEEK CHANGE
-$54.26
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Marco Taglietti
Region: US
Website: scynexis.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: scynexis.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited and R-Pharm, CJSC.
Recent news